As­traZeneca is chang­ing up dos­ing reg­i­mens of its check­point play­er in the face of the pan­dem­ic. The FDA ap­pears ready to make a quick as­sist

Faced with a stub­born glob­al pan­dem­ic, drug­mak­ers are look­ing to change up dos­ing reg­i­mens to re­duce the risk of ex­po­sure to Covid-19 dur­ing med­ical vis­its. And they’re get­ting some quick help from reg­u­la­tors.

On Tues­day morn­ing, As­traZeneca an­nounced it re­ceived FDA pri­or­i­ty re­view for a new reg­i­men of its non-small cell lung can­cer and blad­der can­cer drug Imfinzi, which could cut med­ical vis­its in half.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER